Stock MCRO MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E
Add to a list
To use this feature you must be a member
Log inSign up

Financials Macro Group Pharmaceuticals (Macro Capital) S.A.E

Equities

MCRO

EGS7D971C011

Pharmaceuticals

End-of-day quote Egyptian Exchange
Other stock markets
 18:00:00 2024-06-22 EDT 		5-day change 1st Jan Change
2.02 EGP +0.50% Intraday chart for Macro Group Pharmaceuticals (Macro Capital) S.A.E +0.50% -31.53%
04-16 Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Macro Group Pharmaceuticals (Macro Capital) S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 1,870 1,682
Enterprise Value (EV) 1 1,887 1,833
P/E ratio 10.9 x -6.1 x
Yield 3.25% -
Capitalization / Revenue 2.56 x 3.2 x
EV / Revenue 2.59 x 3.48 x
EV / EBITDA 7.93 x -10.5 x
EV / FCF 24,609,102 x 21,712,949 x
FCF Yield 0% 0%
Price to Book 4.04 x 17.6 x
Nbr of stocks (in thousands) 570,206 570,206
Reference price 2 3.280 2.950
Announcement Date 23-03-02 24-04-16
1EGP in Million2EGP
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 430.5 594.3 729.6 526
EBITDA 1 183.5 206 237.9 -175.2
EBIT 1 181.5 203.6 234.4 -182.4
Operating Margin 42.17% 34.26% 32.12% -34.67%
Earnings before Tax (EBT) 1 177.7 196.5 227.4 -270
Net income 1 135.1 147.9 173.8 -272.7
Net margin 31.39% 24.89% 23.83% -51.83%
EPS 2 0.2300 0.2562 0.3000 -0.4835
Free Cash Flow - -1.347 76.69 84.42
FCF margin - -0.23% 10.51% 16.05%
FCF Conversion (EBITDA) - - 32.24% -
FCF Conversion (Net income) - - 44.12% -
Dividend per Share - 0.0690 0.1067 -
Announcement Date 22-03-07 22-03-07 23-03-02 24-04-16
1EGP in Million2EGP
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 3.87 37.5 17 151
Net Cash position 1 - - - -
Leverage (Debt/EBITDA) 0.0211 x 0.1819 x 0.0713 x -0.8612 x
Free Cash Flow - -1.35 76.7 84.4
ROE (net income / shareholders' equity) - 48.8% 42.4% -97.8%
ROA (Net income/ Total Assets) - 25.8% 20.5% -16.7%
Assets 1 - 573.2 846.6 1,630
Book Value Per Share 2 0.4300 0.6200 0.8100 0.1700
Cash Flow per Share 2 0.1000 0.1000 0.3300 0.1300
Capex 1 7.06 5.81 5.3 6.44
Capex / Sales 1.64% 0.98% 0.73% 1.22%
Announcement Date 22-03-07 22-03-07 23-03-02 24-04-16
1EGP in Million2EGP
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
2.02 EGP
Average target price
5.3 EGP
Spread / Average Target
+162.38%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
MACRO GROUP PHARMACEUTICALS (MACRO CAPITAL) S.A.E Stock Macro Group Pharmaceuticals (Macro Capital) S.A.E
-31.53% 23.84M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.63% 796B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.71% 628B
JOHNSON & JOHNSON Stock Johnson & Johnson
-5.10% 358B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
ABBVIE INC. Stock AbbVie Inc.
+9.95% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.25% 244B
ROCHE HOLDING AG Stock Roche Holding AG
+3.72% 228B
NOVARTIS AG Stock Novartis AG
+12.75% 214B
AMGEN INC. Stock Amgen Inc.
+6.99% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MCRO Stock
  4. Financials Macro Group Pharmaceuticals (Macro Capital) S.A.E